Jesus Vega
Jesus Vega presents content focused on cardiovascular health and nutritional science. His discussions center on evaluating research regarding the effects of taurine on arterial plaque, oxidative stress, inflammation, and atherosclerosis.
8 claims checked on air: 6 supported 2 unverified
What they said on air - supported
Enlicitide (MK-0616) is an oral PCSK9 inhibitor developed by Merck.
"Do you think it has something to do with enlicitide, the new oral PCSK9 inhibitor? ... I think that's from Merck, isn't it?" (said at 0:31:40)
Enlicitide (also designated MK-0616) is an orally bioavailable macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) developed by Merck for the treatment of hypercholesterolemia. Phase 2b and Phase 3 randomized clinical trials have confirmed its efficacy as an oral PCSK9 inhibitor, demonstrating significant LDL-cholesterol reductions of up to approximately 60% to 65%.
Taurine differs from other amino acids in that it is not incorporated into proteins and circulates as a free amino acid.
"taurine has the difference with other amino acids that it is not bound to a protein. It is an amino acid that runs freely and can act on different cells and cell receptors and mechanisms" (said at 0:37:38)
Taurine (2-aminoethanesulfonic acid) is a non-proteinogenic amino acid. Unlike the 20 standard amino acids, taurine contains a sulfonic acid group instead of a carboxyl group and is a beta-amino acid rather than an alpha-amino acid, meaning it is not incorporated into proteins during translation and exists predominantly as a free amino acid in plasma and intracellular fluid.
A published 100-person study by Dave Feldman showed that arterial plaque progression or regression in lean mass hyper-responders was not related to LDL or ApoB levels.
"in his 100-person research, they found some rapid progressors. So some people built some more plaque and some other people actually regressed their plaque. But in all cases, it didn't look like it was anywhere related to LDL or ApoB, which is kind of interesting. That was published." (said at 0:39:15)
The speaker accurately describes the reported findings of a 100-person study co-authored by Dave Feldman (the longitudinal KETO-CTA study). In this 1-year prospective study of 100 individuals following a ketogenic diet with a lean mass hyper-responder (LMHR) lipid profile (LDL-C ≥190 mg/dL, HDL-C ≥60 mg/dL, triglycerides ≤80 mg/dL), coronary computed tomography angiography (CCTA) showed that baseline plaque volume, but not ApoB, baseline LDL-C, or cumulative LDL-C exposure, was associated with coronary plaque progression. The study is observational, non-randomized, and limited by a short 1-year follow-up period. [WARNING: a cited paper has been RETRACTED]
- supports: Longitudinal Data From the KETO-CTA Study: Plaque Predicts Plaque, ApoB Does Not. (JACC. Advances 2025)RETRACTED · cited 12x in the literature
"A total of 100 individuals exhibiting KD-induced LDL-C ≥190 mg/dL, high-density lipoprotein cholesterol ≥60 mg/dL, and triglycerides ≤80 mg/dL were followed for 1 year using coronary artery calcium and coronary computed tomography angiography... Neither change in ApoB (median 3 mg/dL, Q1-Q3: -17 to 35 mg/dL), baseline ApoB, nor total LDL-C exposure (median 1,302 days, Q1-Q3: 984-1,754 days) were associated with the change in noncalcified plaque volume (NCPV) or TPS." (abstract, results)
pubmedfull study (doi)
A coronary artery calcium score does not detect non-calcified soft plaque.
"especially looking for soft plaque, which a calcium score would not tell you" (said at 0:42:10)
A standard non-contrast coronary artery calcium (CAC) scan detects calcified atherosclerotic plaques based on radiodense tissue thresholds (typically >130 Hounsfield units), but it cannot directly visualize non-calcified (soft) plaques. Studies comparing CAC scoring with contrast-enhanced coronary computed tomography angiography (CCTA) consistently demonstrate that non-calcified plaques can be present even in patients with a CAC score of zero.
Aortic valve stenosis narrows the valve orifice, forcing the lower heart chamber to push harder and causing ventricular hypertrophy.
"The problem with aortic stenosis, what happens is that this valve right here doesn't open as it should. So it makes it harder for this chamber on the bottom to send the blood out... your heart has to push harder and these muscle cells from the heart of the lower chambers, they get longer and tired and it gets bigger" (said at 0:49:23)
Aortic stenosis is defined by progressive narrowing and impaired opening of the aortic valve orifice. This increases afterload (resistance to outflow) on the left ventricle (the lower heart chamber), forcing it to generate higher intracavitary pressures to pump blood across the stenotic valve. In response to this chronic pressure overload, the left ventricular myocardium undergoes compensatory remodeling, leading to left ventricular hypertrophy (thickening/enlargement of the muscle walls). Over time, persistent afterload mismatch and maladaptive remodeling can result in cardiomyocyte dysfunction and heart failure.
- supports: Moderate aortic stenosis: Navigating the uncharted. (Echocardiography (Mount Kisco, N.Y.) 2024) · cited 1x in the literature
"Aortic stenosis (AS) stands as the most common valvular heart disease in developed countries and is characterized by progressive narrowing of the aortic valve orifice resulting in elevated transvalvular flow resistance, left ventricular hypertrophy, and progressive increased risk of heart failure and sudden death." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Aortic Stenosis and Heart Failure With Preserved Ejection Fraction: A Cautionary Tale of C… (Circulation. Heart failure 2026)
"Beyond valvular obstruction, many patients with aortic stenosis develop extra-valvular abnormalities, including left ventricular hypertrophy, diastolic dysfunction, and atrial and pulmonary vascular remodeling, which have emerged as major determinants of symptoms and prognosis." (abstract, background, passage verified)
pubmedfull study (doi)
Red blood cell disorders and variations in erythrocyte lifespan can alter hemoglobin A1c (HbA1c) readings.
"There could be some red blood cell issues as well that might impact the A1C." (said at 0:59:45)
Published clinical and review literature firmly establishes that red blood cell disorders and alterations in erythrocyte lifespan or turnover directly affect HbA1c readings. Conditions that reduce red blood cell lifespan or increase turnover (such as hemolytic anemias, hemoglobinopathies like sickle cell trait, or acute blood loss) lower HbA1c values independently of blood glucose. Conversely, conditions associated with decreased erythrocyte turnover or iron deficiency anemia can artificially elevate HbA1c readings.
- supports: The Sickle Effect: The Silent Titan Affecting Glycated Hemoglobin Reliability. (Cureus 2020) · cited 20x in the literature
"Hemoglobin A1c (HbA1c) is a popular invaluable tool in the diagnosis of Type 2 diabetes for red blood cells (RBCs) with a lifespan of 120 days; however, many factors, including hemoglobinopathies, affect its accuracy... It also shows that SCT affects the accuracy of HbA1c, through its likely reduction of RBC lifespan and its increased association with African ancestry and G6PD deficiency." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Critical Relationship Between Iron Deficiency Anaemia (IDA) and Glycated Haemoglobin (HbA1… (Mini reviews in medicinal chemistry 2026)
"The review revealed conflicting findings: some studies reported elevated HbA1c levels in IDA patients independent of glycemic status, potentially leading to diabetes overdiagnosis, while others found no significant association. Proposed mechanisms included altered erythrocyte turnover, structural haemoglobin modifications, and oxidative stress-induced glycation." (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications
No PubMed publication profile has been built for this speaker yet.